Immune-checkpoint inhibitors have revolutionized cancer therapy, yet many patients either
do not derive any benefit from treatment or develop a resistance to checkpoint inhibitors …

Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since
the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 …

Background Lymphocyte-activation gene 3 (LAG-3) is an inhibitory immunoreceptor that
negatively regulates T-cell activation. This paper presents preclinical characterization of the …

Highlights•LAG-3 is a highly important next-generation immune checkpoint molecule.•Ninety-
seven clinical trials are evaluating at least 16 LAG-3-targeting molecules.•Here we identify …

Despite three decades of research to its name and increasing interest in immunotherapies
that target it, LAG-3 remains an elusive co-inhibitory receptor in comparison to the well …

LAG-3 (Lymphocyte activation gene 3) protein is a checkpoint receptor that interacts with
LSEC-tin, Galectin-3 and FGL1. This interaction leads to reduced production of IL-2 and IFN …

Immunotherapy that targets checkpoints, especially programmed cell death protein 1 and
programmed cell death ligand 1, has revolutionized cancer therapy regimens. The overall …

While standard treatment has shown efficacy in patients with breast cancer gene (BRCA)
mutations, recurrence rates are high and additional effective therapies are needed …

Simple Summary As immunotherapy is one of the leading treatment approaches in non-
small cell lung cancer, immunotherapy primary or secondary resistance mechanism need to …

Melanoma, a highly aggressive skin cancer, poses significant challenges in treatment,
particularly for advanced or metastatic cases. While immunotherapy, especially immune …